Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 11/20 | 0.80 |
| ▸ | ERBB2 | P04626 | 4/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.74 |
| ▸ | HTT | P42858 | 3/20 | 0.74 |
| ▸ | MAPT | P10636 | 3/20 | 0.74 |
| ▸ | MEN1 | O00255 | 2/20 | 0.74 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.74 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.74 |
| ▸ | NPC1 | O15118 | 1/20 | 0.74 |
| ▸ | PRNP | P04156 | 1/20 | 0.74 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.74 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.74 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.72 |
| ▸ | FADS1 | O60427 | 1/20 | 0.71 |
| ▸ | LCK | P06239 | 1/20 | 0.69 |
| ▸ | LMNA | P02545 | 2/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.65 |
| ▸ | GMNN | O75496 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11087835 | 0.89 | EGFR (0.80) | EGFRERBB2KDM4EHTTMAPT | |
| SCHEMBL4355658 | 0.89 | EGFR (1.00) | EGFRERBB2KDM4EHTTMAPT | |
| SCHEMBL8871863 | 0.89 | EGFR (0.82) | EGFRERBB2KDM4EHTTMAPT | |
| Hydrochloric Acid SCHEMBL11087783 | 0.88 | EGFR (0.78) | EGFRERBB2KDM4EHTTMAPT | |
| SCHEMBL17532922 | 0.85 | EGFR (0.72) | EGFRERBB2KDM4EHTTMAPT | |
| SCHEMBL4783154 | 0.85 | KDM4E (1.00) | EGFRERBB2KDM4EHTTMAPT | |
| SCHEMBL1262804 | 0.85 | EGFR (1.00) | EGFRERBB2KDM4EHTTMAPT | |
| SCHEMBL31060510 | 0.85 | EGFR (1.00) | EGFRERBB2KDM4EHTTMAPT | |
| SCHEMBL5569927 | 0.85 | KDM4E (0.74) | EGFRERBB2KDM4EHTTMAPT | |
| SCHEMBL2101381 | 0.84 | HTT (1.00) | EGFRERBB2KDM4EHTTMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008089307-A2 | DELTA 5 DESATURASE INHIBITORS FOR THE TREATMENT OF PAIN, INFLAMMATION AND CANCER | LEXICON PHARMACEUTICALS, INC. (US) | 2008-07-24 | — | — | WO | claimed |
| WO-2008089310-A2 | DELTA 5 DESATURASE INHIBITORS FOR THE TREATMENT OF OBESITY | LEXICON PHARMACEUTICALS, INC. (US) | 2008-07-24 | — | — | WO | claimed |
| US-20070123537-A1 | Quinazoline derivatives for the treatment of herpesviral infections | GPC BIOTECH AG (DE) | 2007-05-31 | — | — | US | claimed |
| EP-1673346-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS | GPC Biotech AG (DE) | 2006-06-28 | — | — | EP | claimed |
| WO-2005040125-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS | GPC BIOTECH AG (DE) | 2005-05-06 | — | — | WO | claimed |
| US-6004967-A | TOPICALLY ADMINISTERING 4-(3-BROMOPHENYLAMINO)-6,7-DIMETHOXYQUINAZOLINE TO TREAT HYPERPROLIFERATION CAUSED BY PAPILLOMAVIRUS INFECTION | SUGEN, INC. (US) | 1999-12-21 | — | — | US | claimed |
| EP-0954315-A2 | USE OF QUINAZOLINE DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT IN THE TREATMENT OF HYPERPROLIFERATIVE SKIN DISORDERS | Sugen, Inc. (US) | 1999-11-10 | — | — | EP | claimed |
| WO-1998010767-A9 | USE OF QUINAZOLINE DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT IN THE TREATMENT OF HYPERPROLIFERATIVE SKIN DISORDERS | — | 1998-07-02 | — | — | WO | claimed |
| WO-1998010767-A2 | USE OF QUINAZOLINE DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT IN THE TREATMENT OF HYPERPROLIFERATIVE SKIN DISORDERS | SUGEN, INC. (US) | 1998-03-19 | — | — | WO | claimed |
| US-20240216316-A1 | DIHOMO-GAMMA LINOLENIC ACID (DGLA) IS A NOVEL SENOLYTIC | BUCK INST RES AGING (US) | 2024-07-04 | — | — | US | disclosed |
| US-10842791-B2 | Small molecule inhibitors of EGFR and PI3K | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2020-11-24 | — | — | US | disclosed |
| US-20190167686-A1 | SMALL MOLECULE INHIBITORS OF EGFR AND PI3K | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2019-06-06 | — | — | US | disclosed |
| US-20170088515-A1 | IDENTIFICATION OF COMPOUNDS THAT DISPERSE TDP-43 INCLUSIONS | AQUINNAH PHARMACEUTICALS INC (US) | 2017-03-30 | — | — | US | disclosed |
| US-9359363-B2 | Identification of compounds that disperse TDP-43 inclusions | AQUINNAH PHARMACEUTICALS, INC. (US) | 2016-06-07 | — | — | US | disclosed |
| EP-1673346-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS | GPC Biotech AG (DE) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005040125-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS | GPC BIOTECH AG (DE) | 2005-05-06 | — | — | WO | disclosed |
| US-6004967-A | TOPICALLY ADMINISTERING 4-(3-BROMOPHENYLAMINO)-6,7-DIMETHOXYQUINAZOLINE TO TREAT HYPERPROLIFERATION CAUSED BY PAPILLOMAVIRUS INFECTION | SUGEN, INC. (US) | 1999-12-21 | — | — | US | disclosed |
| EP-0954315-A2 | USE OF QUINAZOLINE DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT IN THE TREATMENT OF HYPERPROLIFERATIVE SKIN DISORDERS | Sugen, Inc. (US) | 1999-11-10 | — | — | EP | disclosed |
| WO-1998010767-A9 | USE OF QUINAZOLINE DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT IN THE TREATMENT OF HYPERPROLIFERATIVE SKIN DISORDERS | — | 1998-07-02 | — | — | WO | disclosed |
| WO-1998010767-A2 | USE OF QUINAZOLINE DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT IN THE TREATMENT OF HYPERPROLIFERATIVE SKIN DISORDERS | SUGEN, INC. (US) | 1998-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10842791-B2 | Small molecule inhibitors of EGFR and PI3K | EGFR, ERBB2, ERBB3 | EGFR 1/4885ERBB2 2/4885KDM4E 2937/4885 |
| US-20190167686-A1 | SMALL MOLECULE INHIBITORS OF EGFR AND PI3K | EGFR, ERBB2, ERBB3 | EGFR 1/4885ERBB2 2/4885KDM4E 2937/4885 |
| US-20240216316-A1 | DIHOMO-GAMMA LINOLENIC ACID (DGLA) IS A NOVEL SENOLYTIC | DAGLA, DAGLB, MGLL | EGFR 2964/4885ERBB2 3512/4885KDM4E 3408/4885 |
| US-20170088515-A1 | IDENTIFICATION OF COMPOUNDS THAT DISPERSE TDP-43 INCLUSIONS | TARDBP, FUS, TIA1 | EGFR 4812/4885ERBB2 4570/4885KDM4E 4233/4885 |
| US-20070123537-A1 | Quinazoline derivatives for the treatment of herpesviral infections | IRF3, PML, TPMT | EGFR 1445/4885ERBB2 1351/4885KDM4E 1004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.